Pulmonx Corporation - Common Stock (LUNG)

Pulmonx (NASDAQ:LUNG) is rebuilding its sales organization, targeting a return to growth and preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year, President and CEO Glen French said during a Canaccord fireside chat. French, who

Net loss narrowed to $10.1 million as cost cuts offset China suspension.

Pulmonx (NASDAQ:LUNG) reported second-quarter revenue of $22.8 million and reiterated its full-year 2026 revenue outlook, while executives highlighted progress in rebuilding the U.S. sales organization, reducing operating expenses and preparing to resume shipments to China. Revenue for the quarter

Pulmonx (LUNG) Q1 2026 Earnings Transcript

Pulmonx (LUNG) Q4 2025 Earnings Call Transcript

In today's session, these stocks are experiencing unusual volume.

Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.

Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.

Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps.

The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.